PMID- 23618405 OWN - NLM STAT- MEDLINE DCOM- 20150330 LR - 20220410 IS - 1757-6512 (Electronic) IS - 1757-6512 (Linking) VI - 4 IP - 2 DP - 2013 Apr 25 TI - Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. PG - 34 LID - 10.1186/scrt194 [doi] AB - INTRODUCTION: Administration of bone marrow mesenchymal stem cells (MSCs) or secreted microvesicles improves recovery from acute kidney injury (AKI). However, the potential roles and mechanisms are not well understood. In the current study, we focused on the protective effect of exosomes derived from human umbilical cord mesenchymal stem cells (hucMSC-ex) on cisplatin-induced nephrotoxicity in vivo and in vitro. METHODS: We constructed cisplatin-induced AKI rat models. At 24 h after treatment with cisplatin, hucMSC-ex were injected into the kidneys via the renal capsule; human lung fibroblast (HFL-1)-secreted exosomes (HFL-1-ex) were used as controls. All animals were killed at day 5 after administration of cisplatin. Renal function, histological changes, tubular apoptosis and proliferation, and degree of oxidative stress were evaluated. In vitro, rat renal tubular epithelial (NRK-52E) cells were treated with or without cisplatin and after 6 h treated with or without exosomes. Cells continued to be cultured for 24 h, and were then harvested for western blotting, apoptosis and detection of degree of oxidative stress. RESULTS: After administration of cisplatin, there was an increase in blood urea nitrogen (BUN) and creatinine (Cr) levels, apoptosis, necrosis of proximal kidney tubules and formation of abundant tubular protein casts and oxidative stress in rats. Cisplatin-induced AKI rats treated with hucMSC-ex, however, showed a significant reduction in all the above indexes. In vitro, treatment with cisplatin alone in NRK-52E cells resulted in an increase in the number of apoptotic cells, oxidative stress and activation of the p38 mitogen-activated protein kinase (p38MAPK) pathway followed by a rise in the expression of caspase 3, and a decrease in cell multiplication, while those results were reversed in the hucMSCs-ex-treated group. Furthermore, it was observed that hucMSC-ex promoted cell proliferation by activation of the extracellular-signal-regulated kinase (ERK)1/2 pathway. CONCLUSIONS: The results in the present study indicate that hucMSC-ex can repair cisplatin-induced AKI in rats and NRK-52E cell injury by ameliorating oxidative stress and cell apoptosis, promoting cell proliferation in vivo and in vitro. This suggests that hucMSC-ex could be exploited as a potential therapeutic tool in cisplatin-induced nephrotoxicity. FAU - Zhou, Ying AU - Zhou Y FAU - Xu, Huitao AU - Xu H FAU - Xu, Wenrong AU - Xu W FAU - Wang, Bingying AU - Wang B FAU - Wu, Huiyi AU - Wu H FAU - Tao, Yang AU - Tao Y FAU - Zhang, Bin AU - Zhang B FAU - Wang, Mei AU - Wang M FAU - Mao, Fei AU - Mao F FAU - Yan, Yongmin AU - Yan Y FAU - Gao, Shuo AU - Gao S FAU - Gu, Hongbing AU - Gu H FAU - Zhu, Wei AU - Zhu W FAU - Qian, Hui AU - Qian H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130425 PL - England TA - Stem Cell Res Ther JT - Stem cell research & therapy JID - 101527581 RN - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) RN - EC 3.4.22.- (Caspase 3) RN - Q20Q21Q62J (Cisplatin) SB - IM CIN - Stem Cell Res Ther. 2013;4(2):39. PMID: 23680102 MH - Acute Kidney Injury/chemically induced/pathology/therapy MH - Animals MH - Apoptosis/*drug effects MH - Caspase 3/metabolism MH - Cell Differentiation MH - Cells, Cultured MH - Cisplatin/*toxicity MH - Exosomes/*metabolism MH - Female MH - Humans MH - Kidney Tubules/drug effects/metabolism/pathology MH - Mesenchymal Stem Cell Transplantation MH - Mesenchymal Stem Cells/*cytology MH - Oxidative Stress/*drug effects MH - Rats MH - Rats, Sprague-Dawley MH - Transplantation, Heterologous MH - Umbilical Cord/*cytology MH - p38 Mitogen-Activated Protein Kinases/metabolism PMC - PMC3707035 EDAT- 2013/04/27 06:00 MHDA- 2015/03/31 06:00 PMCR- 2013/04/25 CRDT- 2013/04/27 06:00 PHST- 2012/11/02 00:00 [received] PHST- 2013/03/08 00:00 [accepted] PHST- 2013/04/27 06:00 [entrez] PHST- 2013/04/27 06:00 [pubmed] PHST- 2015/03/31 06:00 [medline] PHST- 2013/04/25 00:00 [pmc-release] AID - scrt194 [pii] AID - 10.1186/scrt194 [doi] PST - epublish SO - Stem Cell Res Ther. 2013 Apr 25;4(2):34. doi: 10.1186/scrt194.